Tejnaksh Healthcare Ltd

Tejnaksh Healthcare Ltd has submitted its Annual Report for the Financial Year 2025-26 to the BSE. The report includes detailed financial statements, auditor's reports (standalone and consolidated), corporate governance information, and management discussion and analysis. Key personnel and board committees are also detailed within the filing. The company's registered office is in Mumbai, and its hospital and corporate office is located in Dhule, Maharashtra. The company is listed on the BSE with SCRIP CODE 539428 and ISIN INE030T01027.

Tejnaksh Healthcare Ltd has announced that its 19th Annual General Meeting (AGM) will be held on Tuesday, September 29, 2026, at 3:00 P.M. IST. The meeting will be conducted through Video Conferencing/Other Audio Visual Means (VC/OAVM) in compliance with current regulations. The agenda includes receiving and adopting the Audited Financial Statements for the fiscal year 2025-26, appointing Mr. Sanjay Bhikajirao Khatal as Director, and re-appointing Mr. Suhas Vasantrao Thorat as an Independent Director for a second term. Additionally, the company will seek approval for material related party transactions. The AGM notice and Annual Report for FY2025-26, containing e-voting details, have been sent via email to registered shareholders and will be available on the company's website.

Tejnaksh Healthcare Ltd has announced its unaudited financial results for the quarter ended June 30, 2026. The results, which were approved by the Board of Directors on August 13, 2026, cover both standalone and consolidated financials. The company's business primarily falls under 'Medical and Healthcare Services' and operates mainly in India. The filing also notes the impact of new labor codes on gratuity liability, resulting in a reversal recognized as other income. Previous year figures have been regrouped for comparability.

Tejnaksh Healthcare Ltd announced that its Board of Directors met on August 13, 2026. The board considered and approved the Un-Audited Financial Results (Standalone & Consolidated) for the quarter ended June 30, 2026, along with the Limited Review Report. Additionally, the board resolved to reappoint Mr. Suhas Vasantrao Thorat as a Non-Executive Independent Director for a second term, subject to shareholder approval.

Tejnaksh Healthcare Ltd has scheduled a Board of Directors meeting for August 13, 2026, to consider and approve the Un-audited Financial Results (Standalone & Consolidated) for the first quarter ended June 30, 2026. Additionally, the board will discuss the reappointment of Mr. Suhas Vasantrao Thorat as an Independent Director for a second term. The reappointment requires shareholder approval via a special resolution. The trading window for the company's shares will remain closed until 48 hours after the declaration of the financial results.

Tejnaksh Healthcare Ltd has announced the closure of its trading window for promoters, directors, designated employees, and connected persons. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code. The window will remain shut from July 01, 2026, until 48 hours after the declaration of financial results for the quarter and year ended June 30, 2026. This measure is standard practice to prevent potential insider trading during sensitive financial reporting periods.

Tejnaksh Healthcare Ltd has announced its audited financial results for the quarter and year ended March 31, 2026. The results, both consolidated and standalone, were approved by the Board of Directors on May 30, 2026. The audit report, conducted by M/s Maheshwari and Co, Chartered Accountants, expresses an unmodified opinion on the annual audited financial results. The consolidated financial results include the financial results of Tejvedaant Healthcare Private Limited, a subsidiary.

Tejnaksh Healthcare Ltd. has approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The board also re-appointed M/s Kapil Tulsani & Associates as the Internal Auditor for the period April 1, 2026, to March 31, 2027. The company decided against proceeding with the proposed Rights Issue due to postponement of expansion plans. Maheshwari & Co. issued an unmodified opinion on the annual audited financial results.

Tejnaksh Healthcare Ltd has scheduled a Board of Directors meeting on May 30, 2026, to consider and approve the audited financial results (standalone & consolidated) for the quarter and financial year ended March 31, 2026. The trading window closure, which began on March 27, 2026, will remain in effect until 48 hours after the declaration of the audited financial results.

Tejnaksh Healthcare Ltd has announced the closure of its trading window for insider trading. This decision is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's Code of Internal Procedures and Conduct for Prevention of Insider Trading in Securities. The trading window for promoters, directors, designated employees, and other connected or designated persons of the company will be closed from April 01, 2026, till 48 hours after the declaration of Financial Results for the quarter and year ended March 31, 2026.